Experienced in Silicosis

Daniel P. Coutinho

Vila Nova De Gaia, PT 
Experienced in Silicosis
Vila Nova De Gaia, PT 
OverviewLocationsClinical Research

Overview

Daniel Coutinho practices in Vila Nova De Gaia, Portugal. Mr. Coutinho is rated as an Experienced expert by MediFind in the treatment of Silicosis. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Nocardiosis, and Pulmonary Nocardiosis.

His clinical research consists of co-authoring 18 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Silicosis.

Gender
Male

Locations

Vila Nova De Gaia, Portugal
Other Locations
Vouga, Portugal

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase IIb, Randomized, Partially Blind, Active Controlled, Dose-range Finding Study of GSK3640254 Compared to a Reference Arm of Dolutegravir, Each in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1 Infected Antiretroviral Treatment-naive Adults
A Phase IIb, Randomized, Partially Blind, Active Controlled, Dose-range Finding Study of GSK3640254 Compared to a Reference Arm of Dolutegravir, Each in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1 Infected Antiretroviral Treatment-naive Adults
Enrollment Status: Terminated
Publish Date: June 26, 2024
Intervention Type: Drug
Study Drugs: GSK3640254, ABC/3TC, FTC/TAF, Dolutegravir
Study Phase: Phase 2
A Phase IIb, Randomized, Double-blind, Parallel-group Study to Assess the Efficacy, Safety, Tolerability, and Resistance Profile of GSK3640254 in Combination With Dolutegravir Compared to Dolutegravir Plus Lamivudine in HIV-1 Infected, Treatment-naïve Adults
A Phase IIb, Randomized, Double-blind, Parallel-group Study to Assess the Efficacy, Safety, Tolerability, and Resistance Profile of GSK3640254 in Combination With Dolutegravir Compared to Dolutegravir Plus Lamivudine in HIV-1 Infected, Treatment-naïve Adults
Enrollment Status: Terminated
Publish Date: December 14, 2023
Intervention Type: Drug
Study Drugs: GSK3640254, Dolutegravir, Lamivudine
Study Phase: Phase 2
View 1 Less Clinical Trial

18 Total Publications

A multidisciplinary approach to people living with HIV dropping out from treatment-results from a HIV clinic in Portugal.
A multidisciplinary approach to people living with HIV dropping out from treatment-results from a HIV clinic in Portugal.
Journal: International journal of STD & AIDS
Published: September 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Coutinho's expertise for a condition
ConditionClose
        View All 10 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile